# Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

> **NCT04485156** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 926 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** High-dose rifampicin
- **DRUG:** Isoniazid
- **DRUG:** Pyrazinamide
- **DRUG:** Ethambutol
- **DRUG:** Rifampicin

## Key facts

- **NCT ID:** NCT04485156
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2020-09
- **Primary completion:** 2025-08
- **Final completion:** 2026-12
- **Target enrollment:** 926 (ESTIMATED)
- **Last updated:** 2020-07-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04485156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04485156, "Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04485156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*